Skip to content
lifestyle.smarttalksuccess.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nxera Pharma
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
May 6, 2026
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
May 4, 2026
Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award
May 3, 2026
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
May 3, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
May 3, 2026
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
May 3, 2026
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
April 28, 2026
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
February 12, 2026
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
February 12, 2026
←
Previous Page
1
2